Heparan sulfate and cell division by Porcionatto, Marimélia Aparecida et al.
539
Braz J Med Biol Res 32(5) 1999
Heparan sulfate and cell divisionBrazilian Journal of Medical and Biological Research (1999) 32: 539-544
ISSN 0100-879X
Heparan sulfate and cell division
Departamento de Bioquímica, Escola Paulista de Medicina,
Universidade Federal de São Paulo, São Paulo, SP, Brasil
M.A. Porcionatto,
H.B. Nader and
C.P. Dietrich
Abstract
Heparan sulfate is a component of vertebrate and invertebrate tissues
which appears during the cytodifferentiation stage of embryonic
development. Its structure varies according to the tissue and species of
origin and is modified during neoplastic transformation. Several lines
of experimental evidence suggest that heparan sulfate plays a role in
cellular recognition, cellular adhesion and growth control. Heparan
sulfate can participate in the process of cell division in two distinct
ways, either as a positive or negative modulator of cellular prolifera-
tion, or as a response to a mitogenic stimulus.
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Introduction
Heparan sulfate was discovered 50 years
ago by Jorpes and Gardell (1). Nevertheless,
its biological functions are still under inves-
tigation. The heparan sulfate proteoglycans,
that correspond to the glycosaminoglycan
chains covalently linked to a core protein,
are present in all tissues from every species
that show tissue organization, and has a highly
variable structure (2,3) which may account
for at least one of their presumable biologi-
cal roles, i.e., cell-cell recognition (4,5). Also,
heparan sulfates have been implicated in
other biological processes such as interac-
tion with extracellular matrix components
(laminin, fibronectin, collagen) (6), partici-
pation in focal adhesion formation (7), and
cell growth control (8,9). This review fo-
cuses on the possible roles of heparan sul-
fates in cell division.
Heparan sulfate and the control of
cell division
Heparan sulfate can participate in the
process of cell division in two different ways,
either acting as a positive or negative modu-
lator, or as a response to a mitogenic stimu-
lus.
Heparan sulfate as cell growth modulator
Heparan sulfate can either be stimulatory
of cell growth, e.g., when it is a co-receptor
for growth factors, or inhibitory, depending
on the experimental model.
The action of heparan sulfate as a posi-
tive modulator of cell proliferation is due to
its capacity to bind and act as a co-receptor
for growth factors, such as the fibroblast
growth factor (FGF) (Figure 1). Growth fac-
tors are polypeptide molecules that elicit
several responses in target cells. These re-
sponses include proliferation, differentiation,
survival and apoptosis of the cells. FGF, for
instance, binds to the extracellular domain
of its receptor, which is a transmembrane
molecule with protein-tyrosine kinase activ-
ity in the cytoplasmic region. After growth
factor binding, the dimerization of the recep-
tor occurs, followed by autophosphorylation
of the intracellular domain of the receptor.
This process will initiate a signal transduc-
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tion cascade which will generate signals that
reach the nucleus activating the expression
of specific genes, leading to the cellular
response.
It has been extensively reported that pro-
teoglycans, due to their highly negative
charge, bind to several growth factors and
this binding is thought to have an important
regulatory role (10,11). It has also been dem-
onstrated that heparin binds to FGF and is
necessary for its action. As heparin is pres-
ent exclusively inside the cells, the heparan
sulfate proteoglycan would be the candi-
date molecule to play this role in vivo. The
results suggested that both heparin and hep-
aran sulfate proteoglycan may protect FGF
from inactivation and proteolysis (12,13)
and function as a reservoir for the growth
factor which would be released according to
the proliferation needs of the cells (14). Other
data, however, show that heparan sulfate
proteoglycan mediates the binding of FGF to
its high affinity receptor, which bears ty-
rosine kinase activity (15,16).
The potentiation of the mitogenic activ-
ity of aFGF (FGF-1) on 3T3 fibroblasts by
highly sulfated oligosaccharides obtained
from heparin and heparan sulfate has been
demonstrated (17). One curious finding was
that, although heparan sulfates extracted from
several mammalian tissues potentiated the
mitogenic activity of aFGF, in general, they
were less efficient than heparin, on a mass
basis. On the other hand, heparan sulfate
prepared from 3T3-conditioned culture me-
dium proved to be more efficient than hepa-
rin both on a mass and molar basis. These
results suggest that there is a structural speci-
ficity for this interaction.
Members of the FGF family mediate, at
least in part, the outgrowth of the mesoderm
of the developing limb bud in response to the
apical ectodermal ridge. It has been shown
that syndecan-3, a heparan sulfate proteo-
glycan, plays an essential role in this pro-
cess, mediating the interaction of the FGFs
produced by the apical ectodermal ridge with
the underlying mesoderm of the limb bud
(18).
All these results implicate heparan sul-
fate as a positive modulator of mitogenic
stimuli. However, there are several other
results indicating that heparan sulfate, as
well as heparin, can function as an inhibitor
of cell proliferation. The action of heparan
sulfate inhibiting cell proliferation is corre-
HSPG
FGF
Membrane
P P
Active FGF receptorInactive FGF receptor
Figure 1 - Ativaction of fibroblast
growth factor (FGF) receptor by
interaction with the heparan sul-
fate proteoglycan (HSPG)-FGF
complex (modified from Ref. 11).
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lated with the same action exerted by hepa-
rin in a variety of experimental models. Stim-
ulation of quiescent rat mesangial cells with
serum induces the expression of c-fos mRNA.
Addition of heparin and heparan sulfate pre-
pared from rat mesangial cell layers and
conditioned medium inhibits both cell pro-
liferation and expression of c-fos mRNA
(19).
Cell surface heparan sulfate proteogly-
can prepared from log and confluent mono-
layers of a rat hepatoma cell line was added
to a hepatoma cell culture and the prolifera-
tion of the cultures was analyzed (20). The
results showed that heparan sulfate proteo-
glycan synthesized by confluent hepatocytes
prevents cell division due to a block in the G1
phase of the cell cycle prior to the G1/S
transition. On the other hand, heparan sul-
fate proteoglycan synthesized by exponen-
tially growing cultures stimulated cell prolif-
eration.
Transfection of NIH 3T3 cells with the
mouse syndecan-1 cDNA induced high ex-
pression of this heparan sulfate proteogly-
can on the cell surface and increased its
shedding into the culture medium (21). An-
other result of transfection was the inhibi-
tion of bFGF (FGF-2)-induced cell prolif-
eration, suggesting that the expression of
heparan sulfate proteoglycan might provide
a mechanism to restrict the action of FGF.
When heparan sulfate proteoglycans
extracted from rabbit aorta were applied
periadventitially in the rabbit carotid artery
injury model provoked by a balloon catheter,
they played an inhibitory role in neointimal
formation (22). In vitro, the heparan sulfate
proteoglycans maintained smooth muscle
cells in a quiescent state.
These results, together with others, illus-
trate the statement we made at the beginning
of this section, that heparan sulfate proteo-
glycans might play at least two distinct and
apparently opposite biological roles as modu-
lators of cell growth. As has been exten-
sively reported, they might act as positive
effectors of cell proliferation, functioning as
co-receptors for growth factors, such as those
from the FGF family. On the other hand,
heparan sulfate proteoglycans seem to modu-
late cell growth negatively, just like heparin.
Actually, heparin also plays both roles in cell
growth control, and heparan sulfate would
then be the biological molecule involved in
these processes. It is not clear if these oppo-
site actions are a consequence of the distinct
experimental models used or if, in reality,
they are different biological roles played by
heparan sulfate proteoglycans due to the
characteristic structural variability of these
molecules.
Heparan sulfate synthesis and secretion is a
response of cells to mitogenic stimuli
Changes in heparan sulfate synthesis and
secretion during the different phases of the
cell cycle have been described in a few
experimental models and questions still re-
main to be answered. A significant decrease
of heparan sulfate is observed in regenerat-
ing rat liver after partial hepatectomy. The
peak of mitotic activity coincided with the
smallest amounts of heparan sulfate (23).
Also, quiescent cells exhibit an increase in
DNA synthesis after treatment with a crude
extract of Flavobacterium heparinum, which
contains enzymes that degrade heparan sul-
fate (24).
In the early 70s, Kraemer and Tobey
(25) described a premitotic loss of cell sur-
face heparan sulfate in CHO cell culture,
with indications that this loss was not merely
part of a general premitotic secretion of cell
surface components but, rather, a specific
loss. Furthermore, data from studies using
the murine melanoma cell line B16-F10
showed that the turnover of heparan sulfate
and chondroitin sulfate is decreased in the S
phase when compared to the turnover during
the G1 and G2 + M phases (26).
Another experimental model shows that
bovine corneal endothelial cells in culture
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respond to bFGF (FGF-2) by increasing the
amount of heparan sulfate proteoglycan syn-
thesized after stimulation by the growth fac-
tor (27).
We have demonstrated that fetal calf se-
rum specifically stimulates the synthesis of
heparan sulfate proteoglycan by an endothe-
lial cell line derived from rabbit aorta (28).
The effect of serum stimulation on heparan
sulfate synthesis is related to the phase of the
cell cycle. The effect was not observed for
chondroitin sulfate. The synthesis and secre-
tion of heparan sulfate proteoglycan by these
cells is down-regulated during the S phase in
relation to the G1 and G2 + M phases of the
cell cycle, showing a physiologic response
of the cells (Figure 2) (29). The phorbol ester,
phorbol 12-myristate 13-acetate (PMA),
which activates protein kinase C, promotes a
10-fold increase in the amount of heparan
sulfate proteoglycan secreted into the medi-
um. Curiously, the secretion curve along the
cell cycle presents the same pattern as ob-
served for fetal calf serum alone (Figure 2).
We have also reported that PMA causes a
cell cycle block at the G1/S phase transition.
This observation, together with the increase
in heparan sulfate proteoglycan synthesis,
suggests a coordinated cell response elicited
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Figure 2 - Effect of fetal calf se-
rum (FCS) and phorbol 12-myris-
tate 13-acetate (PMA) on the
synthesis of heparan sulfate (HS)
secreted into the culture medi-
um in different phases of the
cell cycle.
by PMA that was not realized before, which
links a cell cycle checkpoint with the me-
tabolism of cell surface proteoglycans.
Heparan sulfate synthesis is mediated by the
activation of protein kinase C
Protein kinase C has a crucial role in
signal transduction for a variety of biologi-
cally active substances, such as growth fac-
tors and hormones, whose activities balance
cellular proliferation and differentiation (30).
On the other hand, PMA was first known for
its tumor-promoting activity (31), and only
later on recognized as a strong and specific
activator of protein kinase C (32), mimick-
ing the natural modulator of this enzyme,
i.e., diacylglycerol (33).
As stated above, PMA specifically stimu-
lates the synthesis of heparan sulfate proteo-
glycan by endothelial cells in culture, an
effect that is likely to be mediated by protein
kinase C activation. Staurosporine and n-
butanol, two kinase inhibitors (34,35), abol-
ish the PMA effect whereas activation of the
cAMP/protein kinase A pathway by both
forskolin and 8-bromo-cAMP is not effec-
tive in triggering stimulation of heparan sul-
fate proteoglycan synthesis.
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In spite of the largely accepted view that
protein kinase C is important in signal trans-
duction mechanisms, it is not known how
the isoforms of this enzyme operate. Specif-
ically, it is not clear how protein kinase C is
located in the regulation circuitry that con-
trols the cell cycle. Therefore, the dual effect
of PMA on this cell line is being considered
in connection with the pathways that regu-
late the gene transcription presumably rel-
evant to cell cycle control. Curiously, the
mapping of the syndecan (heparan sulfate
proteoglycan) genes has shown a linkage
with members of the myc gene family (36).
Also, in vitro experiments have demonstrated
that protein kinase C is able to phosphorylate
two of the four tyrosine residues in the cyto-
plasmic domain of syndecan (37). We are
presently investigating the links between cell
surface proteoglycan metabolism and intra-
cellular regulatory circuitry that maintain
the homeostasis of proliferation and differ-
entiation.
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